Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

PhRMA Fears 'Potentially Limitless' State Suits After Risperdal Case

This article was originally published in The Pink Sheet Daily

Executive Summary

US Supreme Court denies J&J petition seeking review of South Carolina’s $124m judgment related to Risperdal marketing, giving state unfair trade practice laws a boost.


Related Content

Patent Settlements Stir Supreme Court Interest During Slow Term For Pharma Cases
Supreme Court Rejects Most Pharma Cases This Term, But Patent Settlements Stir Interest
Gilead's Pricing Strategy Faces New Opposition Tactics: Patent, Antitrust Suit
J&J Challenges Risperdal Penalty As First Amendment Violation
States Reap Rewards From Solo Suits Against Pharma; Atypical Antipsychotics May Offer Test Cases


Related Companies